All fields are required.

Close Appointment form

Scientific Advisory Board

Improving patient outcomes with innovative drug therapies.

  • Home
  • Scientific Advisory Board

Rajiv Agarwal, M.D., MBBS, FASN, BRCU Faculty

Scientific Advisory Board, Professor of Medicine, Indiana University School of Medicine, Indianapolis, IN

Dr. Agarwal is a tenured Professor of Medicine at Indiana University School of Medicine, where he joined the faculty in 1997. He is a staff physician in the Department of Medicine at Roudebush VA Medical Center in Indianapolis, Indiana. Dr. Agarwal’s scientific investigations focus in the area of hypertension in hemodialysis. Dr. Agarwal has independent NIH support to study hypertension in hemodialysis patients and is recognized as an expert in this field.

He earned his MBBS degree from All India Institute of Medical Sciences (AIIMS), New Delhi, India. In 1993 he completed a Nephrology Fellowship and residency in Internal Medicine and Nephrology from University of Texas, Southwestern Medical Center, Dallas, TX. Dr. Agarwal is an internationally recognized leader in the area of clinical and translational research in nephrology. His research on anemia and iron management among patients with CKD is broadly recognized with his foremost contribution in the area of hypertension in hemodialysis patients. He is a Fellow of the American Heart Association, Fellow of the American Society of Nephrology and an ASH Certified Hypertension Specialist. He serves on Board of Directors of KDIGO, a panelist for Medical Evidence Development Coverage Advisory Committee (MEDCAC) for U.S. Medicare, the editorial board of Kidney International, CJASN, Nephrology Dialysis and Transplantation, Hypertension, Seminars in Dialysis, World Scientific Journal and Current Clinical Pharmacology. He is an Associate Editor of NephSAP and American Journal of Nephrology and the Journal of the American Society of Hypertension.

George R. Aronoff, M.D., M.S., FACP

Vice President, Clinical Affairs, Davita Kidney Care, LLC and Adjunct Professor of medicine and Pharmacology, University of Louisville School of Medicine

Dr. Aronoff’s research focuses on individualization of drug therapy in patients with decreased kidney function. He and his colleagues at the University of Louisville have used artificial intelligence, including model predictive control, to forecast the hemoglobin response to iron and erythropoiesis stimulating agents. He has published more than 150 peer-reviewing journal articles, book chapters and invited reviews in the area of clinical pharmacology. He is the editor of the American College of Physicians’ reference book, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. Dr. Aronoff served as the Division Chief in Nephrology at the University of Louisville for more than 23 years before joining DaVita Kidney Care as Vice President, Clinical Affairs. Dr. Aronoff received a B.A. degree with Distinction from Indiana University and an M.S. degree in Pharmacology and an M.D. with Honors from the Indiana University School of Medicine. He is a member of Phi Beta Kappa and Alpha Omega Alpha honor societies.

Dr. Gary M. Brittenham, M.D.

James A. Wolff Professor of Pediatrics and Professor of Medicine, Columbia University, New York, NY, USA

Dr. Gary M. Brittenham, M.D. is involved in basic and clinical research in iron metabolism and disorders of the red blood cell. His interests include the diagnosis, prevention and treatment of both iron deficiency and iron overload, and the evaluation of iron supplements and iron-chelating agents. His studies have examined acquired and inherited forms of anemia, including thalassemia, sickle cell disorders and other hemoglobinopathies, and the pathogenesis of malarial anemia. He has published more than 230 peer-reviewed journal articles and book chapters in these areas. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. Dr. Brittenham has received awards from the U.S. Public Health Service Award for Exceptional Achievement in Orphan Products Development and from the International Association for the Study of Disorders of Iron Metabolism for Contributions to the Understanding of Disorders of Iron Metabolism and has been a Visiting Professor at universities in the U.S., Europe and Asia. At Columbia University, he has served as Director of the Division of Pediatric Hematology, Department of Pediatrics, and is Executive Director of the St. Giles Comprehensive Sickle Cell – Thalassemia Program. Dr. Brittenham received a B.A. degree with honors from John Hopkins University and a M.D. degree from Case Western Reserve University.

Dr. Alvin L. Crumbliss, Ph.D.

University Distinguished Service Professor of Chemistry at Duke University

Dr. Alvin L. Crumbliss Ph.D. is an internationally recognized expert in iron chemistry and biochemistry. Having authored over 230 peer reviewed journal articles and book chapters in his distinguished career primarily focused on iron bioavailability, oxidative stress, and the relationship between iron and human health and disease. He is a Fellow of the American Association for the Advancement of Science, the American Chemical Society, and the Bass Society (Duke University). Dr. Crumbliss has been a consultant for Rockwell Medical since 2008 and a member of the Scientific Advisory Board since 2011. He is currently the Associate Editor of BioMetals, an Editorial Advisory Board member of Metallomics , and has previously held similar positions with IEEE Sensors Journal, Journal of Inorganic Biochemisty, Inorganic Chemisty and CHEMTRACTS-Inorganic Chemistry. Dr. Crumbliss’ distinguished awards include: Professeur de l’Academie from the French Academy of Sciences, Karcher Medal from Oklahoma University (fix spelling University), Bass Fellow and Bishop-MacDermott Family Professor of Chemistry, Bass Society of Fellows, Herty Medal from the GA Section of the American Chemical Society (ACS), Distinguished Lecturer Award from the NC Section of the ACS, and Alumni Achievement Award from Knox College. Dr. Crumbliss has held visiting faculty positions at universities and research institutes in the US, UK, Italy and France. He has served in several administrative capacities at Duke University, including Chair of the Chemistry Department, Dean of the Natural Sciences, and Dean of the Faculty of Arts & Sciences. Dr. Crumbliss holds a Ph.D. in Chemistry from Northwestern University and a A.B. with College Honors from Knox College.

Ajay Gupta, M.D.

Chief Scientific Officer

Ajay Gupta, M.D., has served as our Chief Scientific Officer and a member of our Scientific Advisory Board since June 2009.

From 2002 to 2009, Dr. Gupta was an Associate Professor of Medicine at UCLA and Charles Drew University Schools of Medicine, where he had an active nephrology practice. He also served on the faculty at Washington University at St. Louis, State University of New York at Syracuse, University of Alabama at Birmingham and Henry Ford Hospital. Dr. Gupta maintains a nephrology practice and is a volunteer faculty member in the Division of Nephrology at University of California at Irvine.

Dr. Gupta is the inventor of delivering soluble ferric pyrophosphate parenterally including by slow continuous intravenous infusion, via the dialysate in hemodialysis and peritoneal dialysis patients, and as an additive to parenteral nutrition admixtures. He has several other patents for drugs, medical devices and diagnostic tests.

Dr. Gupta received a MBBS and completed his residency in internal medicine at AII India Institute of Medical Sciences in New Delhi, a clinical fellowship in Nephrology from Wayne State University and a research fellowship in Nephrology from Washington University at St. Louis. In addition, he is the founder of the Indian Society for Bone and Mineral Research.

Professor Francesco Locatelli, M.D., FRCPB

Scientific Director of the Department of Nephrology, Dialysis and Renal Transplantation at Alessando Manzoni Hospital Lecco, Italy

Professor Locatelli is an internationally known nephrologist and an expert in many fields including anemia. He is a Professor at University of Brescia and Scientific Director of the Department of Nephrology, Dialysis and Renal Transplantation at Alessando Manzoni Hospital Lecco, Italy. He served as past President for: the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA); the International Society of Blood Purification (ISBP); the International Society of Geriatric Nephrology; and the Italian Society of Nephrology. He is a honorary member of Czech Hungarian, Polish, Romanian, Serbian and Turkish Society of Nephrology. He is Doctor honoris causa at Patron University Jasi; a honorable fellow of Royal College of Physician of London, U. K. (FRCP); an International Distinguished Medalist recipient of the Garabed Eknoyan Award of the National Kidney Foundation (NKF); Chairman of the Lombardy Regional Dialysis and Transplantation Registry and finally recipient of the ERA-EDTA 2013 Award for outstanding scientific and clinical achievements. Professor Locatelli has served as Chairman of the Board European Best Practice Guidelines (EBPG); on the board of National Kidney Foundation, Dialysis Outcome Quality Improvement (NKF-DOQI); on the executive board of directors of Kidney Disease: Improving Global Outcomes (KDIGO) and the board of European Renal Best Practice (ERBP). He was President of World Congress of Nephrology 2009 in Milan and is currently President of International Society of Geriatric Nephrology since 2007 and Council Member of International Society of Nephrology (ISN). Professor Locatelli also serves on the editorial board of numerous journals, including Nephrology Dialysis and Transplantation (NDT) and the Journal of the American Society of Nephrology (JASN) and serves as reviewer of many professional journals including The New England Journal of Medicine and The Lancet.

Iain Macdougal, BSc(Hons), MB, ChB, M.D., FRCP

Consultant Nephrologist and Honorary Senior Lecturer at King's College Hospital, London

Dr. Iain C. Macdougall is a Consultant Nephrologist and Professor of Clinical Nephrology and R&D Lead, Renal Dept.at King’s College Hospital, London since 1996 and South London Renal CLRN lead for the NIHR network. His major research interests are in the field of renal anemia. Dr. Macdougall has led numerous Phase I, II and III pivotal multicenter clinical trials shaping the management of renal anemia worldwide fororal iron, intravenous iron, and ESAs including erythropoietin, darbepoetin, C.E.R.A., and Hematide. Dr. Macdougall has published over 160 peer reviewed research publications and has been a member of both US and European anemia guidelines working groups. He has served at the American Society of Nephrology, European Renal Association, Renal Association and Royal Society of Medicine.